-

Salesforce’s Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world’s #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliver life-changing medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, and respiratory and immunology.

With Agentforce Life Sciences, Salesforce aims to help AstraZeneca unlock a new era of intelligent engagement — redefining customer relationships and accelerating business growth. The partnership will enable teams to focus on strategic customer outcomes and meaningful customer interactions.

Expanding its remit for AstraZeneca, Salesforce will support Agentforce 360 for Life Sciences as the global, end-to-end engagement solution for AstraZeneca, including:

  • Medical-Commercial Coordination: Consolidating healthcare professional (HCP) insights and surface context across teams.
  • Personalized Engagement: Scaling operations across key account, reimbursement, and field teams with next-best action recommendations. AstraZeneca will also orchestrate and automate digital campaigns across multiple channels based on customer preferences.
  • Model Context Protocol (MCP) Interoperability: Extending its composable architecture with Salesforce’s Agent Fabric, AstraZeneca will orchestrate internal and external agent actions across field engagement, commercial operations, and different brands and regions, allowing its care teams and AI agents to work seamlessly together.

“This partnership with AstraZeneca represents a clear step towards building intelligent, agentic customer engagement in the life sciences industry with their selection of Agentforce Life Sciences for Customer Engagement,” said Frank Defesche, SVP and GM of Life Sciences at Salesforce. “Together, we will empower AstraZeneca’s teams with the latest technology to deliver personalized engagement and accelerate the delivery of life-changing medicines to patients around the world.”

Learn more:

About Salesforce

Salesforce helps organizations of any size become Agentic Enterprises — integrating humans, agents, apps, and data on a trusted, unified platform to unlock unprecedented growth and innovation. Visit www.salesforce.com for more information.

Any unreleased services or features referenced here are not currently available and may not be delivered on time or at all. Customers should make their purchase decisions based upon features that are currently available.

Contacts

Maha Neouchy
Salesforce
Public Relations
408-568-8442
pr@salesforce.com

Salesforce

NYSE:CRM

Release Versions

Contacts

Maha Neouchy
Salesforce
Public Relations
408-568-8442
pr@salesforce.com

More News From Salesforce

Salesforce Announces the General Availability of Slackbot – Your Personal Agent for Work

SAN FRANCISCO--(BUSINESS WIRE)--AI has changed our personal lives, answering any question, unleashing our creativity, and delivering tailored insights with a simple prompt. But in the workplace, AI hasn’t yet been so transformative — bogged down by unintuitive interfaces, fragmented across multiple teams and tools, beset by hallucinations and inconsistency, and lacking the context that the workplace demands. At Dreamforce, we unveiled our vision for closing this gap: Agentforce 360 with Slack a...

Salesforce Grants Equity Awards to Regrello Employees Under Its Inducement Equity Incentive Plan

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the #1 AI CRM, today announced it has granted equity awards under its 2014 Inducement Equity Incentive Plan (the "Plan") to new employees who joined Salesforce in connection with the acquisition of Regrello. The Plan was adopted by the Salesforce Board of Directors in July 2014, in accordance with New York Stock Exchange Rule 303A.08. Under the Plan, Salesforce granted a total of 222,453 restricted stock units ("RSUs") to 55 employees at R...

Salesforce’s Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative medicines company, has selected Salesforce’s Agentforce Life Sciences for Customer Engagement to connect patient and healthcare professional (HCP) experiences, enabling teams to focus on strategic and meaningful customer interactions. Building upon its existing investments with Agentforce Health, Data 360 for Health & Life Sciences, MuleSoft f...
Back to Newsroom